The pathophysiological mechanism behind the possible role of MPO as an actor in adverse ventricular remodeling and heart failure development after AMI has been suggested to be decreased inactivation of plasminogen activator inhibitor-1 (PAI-1) by MPO-generated oxidants with resultant decreased plasmin activity [11]. This evidence concerns the gene PLG and heart failure.